Patients with a diagnosis of heart, renal or liver failure, a systemic inflammatory or metabolic disorder or a moderate/severe exacerbation (i.e. requiring antibiotics, oral steroids, or hospitalisation) in the preceding 4 weeks were excluded. 25 healthy age-matched controls (11 female and 14 male) were recruited by advertisement. All subjects gave written informed consent 
Measurement of circulating plasma miRNA levels
The method followed was adapted from Kroch et al 7 . Briefly, 4ml of Qiazol Lysis reagent solution (Invitrogen) was added to 400µl of thawed plasma sample, vortexed and left to stand for 5 minutes.
A stock of synthetic C. elegans miRNA, (concentration 5 fmol/µL) was prepared to use as a spiked-in exogenous control Sequences: Cel-miR-39, 5'-UCACCGGGUGUAAAUCAGCUUG-3'; Cel-miR-54, 5'-CGUAAUCUUCAUAAUCCGAG-3' (Invitrogen). 5µl of this was added to the denatured plasma sample and vortexed.
300µl of molecular grade chloroform was then added to the sample, vortexed for 30 seconds and centrifuged for 25 minutes at 2,500 x g at 4°C. The aqueous phase for each sample was then transferred to a new collecting tube and RNA was isolated using the miRNeasy Mini RNA isolation kit according to the manufacturer's protocol (Qiagen, Inc). RNA Samples were eluted from the columns in 50µl RNAse free water and stored at -80°C.
For microRNA cDNA synthesis and poly (A) tailing from RNA, an NCode ™ VILO™ miRNA cDNA Synthesis kit was used according to the manufacturer's guidelines. 11µl of RNA was pipetted into one well on a 96 well plate, in which the cDNA was later stored. RNA was heated to 65°C for 5 minutes, and then placed on ice for 2 minutes. cDNA master mix was prepared (each reaction contained 4µl of 5X reaction, 2µl of 10X SuperScript enzyme mix and 3µl of DPEC water). 9µl of this master mix was then added to the heated RNA. The reaction was then incubated at 37°C for one hour and terminated by heating to 95°C for 5 minutes. 80µl of sterile water was then added to give a total RT product volume of 100µl of cDNA. cDNA was stored at -20°C. 
Polymerase chain Reaction (PCR)

Quantitative real-time PCR
Express Sybr® GreenER™ miRNA qRT-PCR kit was used according to the manufacturer's guidelines Each sample was tested in duplicate on 96 well plates, equal number of controls were on each plate.
We measured miR-1, miR-499, miR-206, miR-181 and miR-133. Two miRNAs known not to be muscle restricted (miR-16 and miR-122) served as controls.
Analysis was performed as previously described. Results were normalised to an exogenous spiked in control, C. elegans miR-39. Samples where duplicates gave inconsistent results were excluded from the analysis. Average Ct value for the patients was 18.9 ± 2.1 and for the controls was 19.4 ± 2.3 (mean ± SD) these values were not significantly different.
Muscle analysis
MHC mRNA analysis
Real time quantitative PCR (RT-PCR): RNA was extracted from muscle biopsies using the Qiagen RNeasy ® kit (Qiagen, UK), the concentration of RNA was quantified using a spectrophotometer (Nanodrop (ND1000, Wilmington USA) and first strand cDNA generated using Superscript .
Transcription factor Enzyme linked Immunsorbent Assays (TF ELISAS) to quantify NFκβ P65 and P50
subunits in quadriceps muscle biopsies 10ug protein per sample was analysed. Assays were performed by the US Panomics/Affymetrix testing Service in California, USA using the Panomics/Affymetric TF ELISA plates, solutions and nuclear extraction kit (#EK1111, #EK1121 and EK1041). Samples were run in duplicate with appropriate positive controls (HeLa cell nuclear extracts treated with TNF-α) and negative controls.
The average result for each sample was calculated for purposes of analysis.
Luminex assays for Plasma cytokines.
Plasma cytokines were determined using luminex assays run by European Invitrogen Testing Service.
An ultrasensitive panel was run to determine TNF-α, IL-2 and IL-5 with a sensitivity of <1pg/ml for each analyte (#LHC6004) and standard panels used to quantitate CRP (#LHP0031) and TNF-α receptors I and II (TNFRI and TNFRII, #LHC0006).
Statistical analysis:
PCR data were log transformed to stabilise the variance in the dataset as variance increases with Ct value and to give equal weighting to samples with low levels. Pearson's correlation coefficient was calculated to analyse correlations assuming linearity. Differences between patients and controls were calculated by Student's t-test for normally distributed data and by Mann-Whitney U test for data that did not fit a normal distribution. Comparison of single variables across the GOLD stages was performed by ANOVA and the analysis corrected for multiple testing using a Bonferroni-Dunn Correction.
ROC analysis: samples were defined as exhibiting type I fibre shift if the proportion of fibres in the biopsy was below the 2.5 th percentile for the control group (less that 31% type I fibres).
Physiological values and log normalised miRNA values were used alone or combined by multiplication to give a score as the variable for ROC analysis. All values were multiplied by -1 to classify patients according to the presence of type I fibre-shift. ROC analysis was performed in Aabel (Gigawiz). Statistical significance was taken at p<0.05 for all analyses. Analyses were performed using Table S1 : Physiological, muscle and plasma miR levels according to disease status Parameters were measured as described in Materials and Methods and are shown as median (inter-quartile range). ** p<0.005 as determined by ANOVA, adjusted =0.005. These data describe the values from the subjects included in this study. Figure S1 . Association of physiological characteristics with disease status FFMI, 6 MW (% predicted) and strength measured as MVC/wt as described in methods were compared across the GOLD stages. FFMI was suppressed in GOLD III and GOLD IV patients compared to controls and to GOLD II patients (there were too few GOLD I patients for proper analysis). GOLD II, GOLD II and GOLD IV patients had lower endurance marked by 6MW% predicted than controls with GOLD IV patients having the lowest endurance. There were no significant differences in strength between the groups. (** p<0.005 vs control, † †p<0.005 vs GOLD II, † † †p<0.005 GOLD III vs GOLD IV, ANOVA adjusted =0.005). . Figure S6 ROC analyses of plasma miRNA levels to discriminate patients according to presence of type I fibre-shift GOLD III and IV patients were defined as having type I fibre-shift or not as described in Results. ROC analysis was then performed as described in Materials and Methods using plasma levels of; miR-1 (A), miR-206 (B), miR-181 (C), miR-499 (D). Areas under the curves are shown for each miR.
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